ArhGAP30 promotes p53 acetylation and function in colorectal cancer

Nature Communications

Volumn 5, Issue , 2014, Pages

  Wang, Jilin ^a   Qian, Jin ^a   Hu, Ye ^a   Kong, Xuan ^a   Chen, Haoyan ^a   Shi, Qinghua ^b   Jiang, Long ^b   Wu, Chenming ^c   Zou, Weiping ^d   Chen, Yingxuan ^a   Xu, Jie ^a   Fang, Jing Yuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARHGAP30 PROTEIN; DNA; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; LYSINE; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ARHGAP30 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

CANCER; ENZYME ACTIVITY; GENE EXPRESSION; PROTEIN;

ACETYLATION; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROTEIN BINDING; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; CELL MOTION; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MALE; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; REFERENCE VALUE;

ACETYLATION; ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL MOVEMENT; COLORECTAL NEOPLASMS; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GTPASE-ACTIVATING PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE, INBRED BALB C; REFERENCE VALUES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907334161     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5735     Document Type: Article

References (56)

1. Goh, A. M. & Lane, D. P. How p53 wields the scales of fate: arrest or death? Transcription 3, 240-244 (2012).
2. Tan, E. H. et al. Functions of TAp63 and p53 in restraining the development of metastatic cancer. Oncogene 33, 3325-3333 (2014).
3. Maddocks, O. D. et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493, 542-546 (2013).
4. Lujambio, A. et al. Non-cell-autonomous tumor suppression by p53. Cell 153, 449-460 (2013).
5. Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268-1286 (2012).
6. Berkers, C. R., Maddocks, O. D., Cheung, E. C., Mor, I. & Vousden, K. H. Metabolic regulation by p53 family members. Cell. Metab. 18, 617-633 (2013).
7. Jiang, P., Du, W., Mancuso, A., Wellen, K. E. & Yang, X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 493, 689-693 (2013).
8. Hong, H. et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460, 1132-1135 (2009).
9. Swaminathan, S. et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat. Med. 19, 1014-1022 (2013).
10. Follis, A. V. et al. PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Nat. Chem. Biol. 9, 163-168 (2013).
11. Vaseva, A. V. et al. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149, 1536-1548 (2012).
12. Purvis, J. E. et al. p53 dynamics control cell fate. Science 336, 1440-1444 (2012).
13. Marcel, V. et al. p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. Cancer Cell 24, 318-330 (2013).
14. Kenzelmann Broz, D. et al. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev. 27, 1016-1031 (2013).
15. Aylon, Y. & Oren, M. New plays in the p53 theater. Curr. Opin. Genet. Dev. 21, 86-92 (2011).
16. Matissek, K. J., Mossalam, M., Okal, A. & Lim, C. S. The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondria. Mol. Pharm. 10, 3592-3602 (2013).
17. Liu, G., Xia, T. & Chen, X. The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREBbinding protein. J. Biol. Chem. 278, 17557-17565 (2003).
18. Muller-Tiemann, B. F., Halazonetis, T. D. & Elting, J. J. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc. Natl Acad. Sci. USA 95, 6079-6084 (1998).
19. McKinney, K. & Prives, C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol. Cell Biol. 22, 6797-6808 (2002).
20. Krummel, K. A., Lee, C. J., Toledo, F. & Wahl, G. M. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl Acad. Sci. USA 102, 10188-10193 (2005).
21. Feng, L., Lin, T., Uranishi, H., Gu, W. & Xu, Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell Biol. 25, 5389-5395 (2005).
22. Simeonova, I. et al. Mutant mice lacking the p53 C-terminal domain model telomere syndromes. Cell Rep. 3, 2046-2058 (2013).
23. Ahn, J. & Prives, C. The C-terminus of p53: the more you learn the less you know. Nat. Struct. Biol. 8, 730-732 (2001).
24. Carter, S., Bischof, O., Dejean, A. & Vousden, K. H. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat. Cell Biol. 9, 428-435 (2007).
25. Gembarska, A. et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat. Med. 18, 1239-1247 (2012).
26. Daftuar, L., Zhu, Y., Jacq, X. & Prives, C. Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS ONE 8, e68667 (2013).
27. Wade, M., Li, Y. C. & Wahl, G. M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 13, 83-96 (2013).
28. Lu, M. et al. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell 23, 618-633 (2013).
29. Bista, M., Petrovich, M. & Fersht, A. R. MDMX contains an autoinhibitory sequence element. Proc. Natl Acad. Sci. USA 110, 17814-17819 (2013).
30. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. & Gu, W. Acetylation is indispensable for p53 activation. Cell 133, 612-626 (2008).
31. Yamaguchi, H. et al. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J. Biol. Chem. 284, 11171-11183 (2009).
32. Kim, J. H. et al. p53 acetylation enhances Taxol-induced apoptosis in human cancer cells. Apoptosis 18, 110-120 (2013).
33. de Conti, A. et al. The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway. Carcinogenesis 34, 1900-1906 (2013).
34. Marouco, D., Garabadgiu, A. V., Melino, G. & Barlev, N. A. Lysine-specific modifications of p53: a matter of life and death? Oncotarget 4, 1556-1571 (2013).
35. van Leeuwen, I. M. et al. Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2. Mol. Cancer Ther. 12, 471-480 (2013).
36. Rokudai, S. et al. MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc. Natl Acad. Sci. USA 110, 3895-3900 (2013).
37. Kim, W. J., Rivera, M. N., Coffman, E. J. & Haber, D. A. The WTX tumor suppressor enhances p53 acetylation by CBP/p300. Mol. Cell 45, 587-597 (2012).
38. Kuroda, T. et al. RNA content in the nucleolus alters p53 acetylation via MYBBP1A. EMBO J. 30, 1054-1066 (2011).
39. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010).
40. Naji, L., Pacholsky, D. & Aspenstrom, P. ARHGAP30 is a Wrch-1-interacting protein involved in actin dynamics and cell adhesion. Biochem. Biophys. Res. Commun. 409, 96-102 (2011).
41. Agesen, T. H. et al. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 61, 1560-1567 (2012).
42. Menendez, D. et al. Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Res. 41, 7286-7301 (2013).
43. Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
44. Drost, J. et al. BRD7 is a candidate tumour suppressor gene required for p53 function. Nat. Cell Biol. 12, 380-389 (2010).
45. Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606 (1997).
46. Davison, T. S., Yin, P., Nie, E., Kay, C. & Arrowsmith, C. H. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene 17, 651-656 (1998).
47. Xu, J. et al. RhoGAPs attenuate cell proliferation by direct interaction with p53 tetramerization domain. Cell Rep. 3, 1526-1538 (2013).
48. Farre, D. et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 31, 3651-3653 (2003).
49. Song, J. H. et al. The APC network regulates the removal of mutated cells from colonic crypts. Cell Rep. 7, 94-103 (2014).
50. Wen, Z. et al. Orphan nuclear receptor PNR/NR2E3 stimulates p53 functions by enhancing p53 acetylation. Mol. Cell Biol. 32, 26-35 (2012).
51. Wu, D., Ozaki, T., Yoshihara, Y., Kubo, N. & Nakagawara, A. Runt-related transcription factor 1 (RUNX1) stimulates tumor suppressor p53 protein in response to DNA damage through complex formation and acetylation. J. Biol. Chem. 288, 1353-1364 (2013).
52. Kong, X. et al. Synbindin in extracellular signal-regulated protein kinase spatial regulation and gastric cancer aggressiveness. J. Natl Cancer. Inst. 105, 1738-1749 (2013).
53. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
54. Li, H., Ruan, J. & Durbin, R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res. 18, 1851-1858 (2008).
55. Valouev, A. et al. Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data. Nat. Methods 5, 829-834 (2008).
56. Zhu, L. J. et al. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics 11, 237 (2010).